Trials / Recruiting
RecruitingNCT06743035
Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly
Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly: A Prospective, Longitudinal, Multicenter, Observational Study in Germany
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- iOMEDICO AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this non interventional study is to evaluate symptom burden in adult patients with PV without symptomatic splenomegaly during treatment with ropeginterferon alfa-2b in a real-world setting. Further patient-relevant endpoints include effectiveness including complete hematologic response (CHR), event-free survival (EFS), safety and tolerability, treatment reality including dosing details as well as factors affecting treatment decision making.
Conditions
Timeline
- Start date
- 2024-12-03
- Primary completion
- 2029-07-01
- Completion
- 2029-07-01
- First posted
- 2024-12-19
- Last updated
- 2026-01-09
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT06743035. Inclusion in this directory is not an endorsement.